Share
Rick R. Suarez
AstraZeneca has appointed Rick R. Suarez as Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit.
In this role, Suarez will lead the company’s US BioPharmaceuticals organization with full responsibility for portfolio performance, commercial execution, and long-term growth across AstraZeneca’s largest market.
Suarez will oversee the execution of AstraZeneca’s previously announced $50 billion investment in the United States, spanning research, development, and manufacturing. A central element of this commitment includes the construction of a US$4.5 billion manufacturing facility in Virginia, representing the company’s largest single manufacturing investment globally.
This significant expansion supports AstraZeneca’s ambition to achieve $80 billion in total revenue by 2030, with approximately half expected to be generated from the US market.
With more than 20 years of experience in the US healthcare sector, Suarez brings deep institutional knowledge and proven leadership across commercial, medical, and market access functions. He has held multiple senior roles within AstraZeneca and is recognized for driving strong performance and operational excellence across complex organizations.
Suarez returns to the US following his tenure as Country President for Spain, a role he assumed in 2020. During this period, he led one of AstraZeneca’s strongest-performing European markets, expanded Spain’s contribution to global clinical development, and positioned Barcelona as a strategic innovation hub. He also established a new global hub in the city and launched the AstraZeneca Healthcare Innovation Hub, committing more than US$10 million to digital health and data-driven initiatives focused on translational innovation.
Suarez will be based at AstraZeneca’s US headquarters in Wilmington, Delaware.
